PALO ALTO, Calif., April 14, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated, a biopharmaceutical company focused on the development and commercialization of therapies for Orphan Diseases, announced today the appointments of Joanne Quan, M.D., as the Company's Chief Medical Officer and Shelly Xiong, Ph.D., as the Company's Vice President of Regulatory Affairs.
David Cory, President and Chief Executive Officer of Eiger, commented, "We are proud to appoint Dr. Quan as our Chief Medical Officer and Dr. Xiong as our Vice President of Regulatory Affairs at this critical time in the Company's evolution. They bring many years of complementary, relevant experience overseeing the complete development and regulatory strategy of multiple programs, including Orphan Diseases, at both biotech and pharmaceutical companies. This combined experience will be tremendously useful as we shape strategy for the future Eiger Orphan Disease pipeline."
Dr. Quan was most recently Vice President, New Product Clinical Development at InterMune. Previously, she was VicePresident, Clinical Development at Arena Pharmaceuticals and led the collaboration with Eisai for lorcaserin (BELVIQ) as well as pipeline planning for Arena, including initiation of a Phase 2 program in Pulmonary Arterial Hypertension (PAH). Prior to this, Dr. Quan held scientific, clinical and regulatory positions of increasing responsibility at Bayhill Therapeutics, Alza (Johnson and Johnson), Genentech, and PathoGenesis. She has led multiple successful collaborations and project teams, several IND/CTA submissions and designed, conducted and analyzed numerous Phase 1-4 clinical trials in multiple therapeutic areas, many in orphan diseases. Dr. Quan received a B.A. in Molecular Biology at the University of California, Berkeley and an M.D. at Stanford University School of Medicine. She completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Pulmonary and Critical Care Medicine at the University of Washington, Seattle.
Dr. Xiong most recently served as Director of Regulatory Affairs at InterMune where she was responsible for establishing and managing the regulatory labeling function for European commercialization and US labeling preparation for Esbriet for Idiopathic Pulmonary Fibrosis (IPF). Previously, she was at Gilead in positions of increasing responsibility in clinical virology and regulatory affairs and led the clinical virology program for Hepsera for HBV from Phase 2 through product approval. While at Gilead, she was involved in multiple IND and NDA filings as well as commercial product labeling for antiviral programs with FDA and in China with CFDA. She served as Director of China Operations at Covance in Shanghai and was responsible for business strategy, client and government interaction. Dr. Xiong received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.
Eiger is a privately held biotechnology company focused on the research, development and commercialization of innovative therapies for Orphan Designation Diseases. The company is focused on developing lonafarnib for the treatment of Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis. Lonafarnib is not approved for sale. For additional information about Eiger and its R&D pipeline, please visit www.eigerbio.com.
Investors: Jim Shaffer, Eiger BioPharmaceuticals, Inc., 919-345-4256, [email protected]
SOURCE Eiger BioPharmaceuticals, Inc.